These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 25995443)

  • 41. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
    Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B
    Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
    Grønlund B
    Dan Med Bull; 2006 Aug; 53(3):232-57. PubMed ID: 17092448
    [No Abstract]   [Full Text] [Related]  

  • 43. BRCA Mutation Status Is Not Associated With Increased Hematologic Toxicity Among Patients Undergoing Platinum-Based Chemotherapy for Ovarian Cancer.
    Kotsopoulos J; Willows K; Trat S; Kim RH; Volenik A; Sun P; Narod SA; Boyd J; May T
    Int J Gynecol Cancer; 2018 Jan; 28(1):69-76. PubMed ID: 29194191
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
    Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
    Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
    Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
    Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
    Zhang J; Chen AP; Wang B; Zhao SP; Liu LZ; Dai SZ
    Ai Zheng; 2008 Dec; 27(12):1331-6. PubMed ID: 19080004
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prediction of chemotherapeutic resistance in serous ovarian cancer with low-density custom microarray.
    Zhu HL; Zeng HX; Liang XD; Chang XH; Wang JL; Cui H; Wei LH
    Chin Med J (Engl); 2020 Apr; 133(7):871-873. PubMed ID: 32106126
    [No Abstract]   [Full Text] [Related]  

  • 48. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
    Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Low-grade serous, mucinous carcinoma].
    Nakayama K; Kyo S
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):179-82. PubMed ID: 25834916
    [No Abstract]   [Full Text] [Related]  

  • 50. Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer.
    Pietzner K; Woopen H; Richter R; Joens T; Braicu EI; Dimitrova D; Mellstedt H; Darb-Esfahani S; Denkert C; Lindhofer H; Fotopoulou C; Sehouli J
    Int J Gynecol Cancer; 2013 Jun; 23(5):797-802. PubMed ID: 23694980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry.
    Alberti N; Serrano-Egea A; García-García E; Ballestín C; Pérez-Barrios A; López-Ríos F; de Agustín P
    Acta Cytol; 2007; 51(2):203-6. PubMed ID: 17425204
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?
    Ayhan A; Taskiran C; Yigit-Celik N; Bozdag G; Gultekin M; Usubutun A; Guler N; Yuce K
    Int J Gynecol Cancer; 2006; 16(2):484-9. PubMed ID: 16681715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
    Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
    Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
    Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response on: reduced expression of NDUFS3 and its clinical significance in serous ovarian cancer.
    Piek JM
    Int J Gynecol Cancer; 2013 Oct; 23(8):1348. PubMed ID: 24257547
    [No Abstract]   [Full Text] [Related]  

  • 57. The changing view of high-grade serous ovarian cancer.
    Berns EM; Bowtell DD
    Cancer Res; 2012 Jun; 72(11):2701-4. PubMed ID: 22593197
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.
    Lee J; An S; Choi YM; Lee J; Ahn KJ; Lee JH; Kim TJ; An IS; Bae S
    Int J Oncol; 2016 Nov; 49(5):1945-1952. PubMed ID: 27600258
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting MAPK in recurrent, low-grade serous ovarian cancer.
    Blagden SP
    Lancet; 2022 Feb; 399(10324):499-501. PubMed ID: 35123677
    [No Abstract]   [Full Text] [Related]  

  • 60. Chemotherapy changes the DNA ploidy in ovarian cancer.
    Venesmaa P; Paavonen J; Forss M; Ylikorkala O
    Br J Obstet Gynaecol; 1995 Jul; 102(7):568-9. PubMed ID: 7647063
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.